Source: Mass High Tech

 Cambridge-based biotech startup Catabasis Pharmaceuticals Inc. has raised about $2 million in an amendment to a filing with the U.S. Securities and Exchange Commission.

The company develops drugs to treat inflammatory diseases, according to its website. The developments are aimed at improving the conditions of inflammatory bowel disease, diabetes, psoriasis, rheumatoid arthritis and multiple sclerosis. Catabasis claims it has already demonstrated in vitro and in vivo proof of concept for its CAT1000 compounds.

The $2 million funds stem from an intended $3 million debt round.

Christopher Thomajan, chief financial officer of Catabasis, was not immediately available to discuss the filing.
The company previously filed an amendment to an SEC filing in May, noting that it had raised $1.075 million of a $2 million debt round. Read more here